HCV: The Journey from Discovery to a Cure

Volume I

  • Michael J. Sofia

Part of the Topics in Medicinal Chemistry book series (TMC, volume 31)

Table of contents

  1. Front Matter
    Pages i-viii
  2. The Virus & Early Therapy

    1. Front Matter
      Pages 1-1
    2. Michael Houghton
      Pages 19-27
    3. Mohsan Saeed, Eva Billerbeck, Charles M. Rice
      Pages 29-68
    4. Ralf Bartenschlager, Volker Lohmann
      Pages 69-96
    5. Saleh A. Alqahtani, Mark S. Sulkowski
      Pages 97-113
  3. HCV NS5B Polymerase Inhibitors

  4. HCV NS3/4a Protease Inhibitors

    1. Front Matter
      Pages 229-229
    2. Nigel J. Liverton
      Pages 231-259
    3. Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola, Li-Qiang Sun
      Pages 317-354
    4. John A. McCauley, Michael T. Rudd
      Pages 355-387
    5. Keith F. McDaniel, Yi-Yin Ku, Ying Sun, Hui-Ju Chen, Jason Shanley, Timothy Middleton et al.
      Pages 389-413
    6. Guoqiang Wang, Jun Ma, Li-Juan Jiang, Yonghua Gai, Jiang Long, Bin Wang et al.
      Pages 415-440
  5. Back Matter
    Pages 459-463

About this book


Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.

This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".


HCV genome Molecular Virology HCV replicon system IFN therapy Polymerase Inhibitors Sofosbuvir Beclabuvir Protease inhibitors HCV treatment

Editors and affiliations

  • Michael J. Sofia
    • 1
  1. 1.Arbutus Biopharma, Inc.WarminsterUSA

Bibliographic information

Industry Sectors
Chemical Manufacturing